The Use of a Cognitive Protectant to Help Maintain Quality of Life and Cognition in Premenopausal Women with Breast Cancer Undergoing Adjuvant Chemotherapy
Abstract
Women undergoing chemotherapy for a diagnosis of breast cancer experience a decrease in quality of life and, particularly, a reduction in cognitive function, both during and subsequent to therapy. To target the quality of life and cognitive function in pre-menopausal women undergoing chemotherapy, the authors plan to evaluate the effects of chemotherapy on cognitive function, quality of life, and fatigue. Pre-menopausal women with breast cancer receiving adjuvant or neoadjuvant chemotherapy, including either adriamycin or epirubicin, plus cyclophosphamide every 2 or 3 weeks will be recruited to participate in the study. Evaluations of the study endpoints will be done prior to receiving the first cycle, prior to initiating the third cycle, and approximately 3 weeks after completing the final cycle of chemotherapy, but prior to any additional treatment. Eligible subjects will complete a series of self- and staff-administered tests. The results will be compared with other factors, including serum hormone levels, hemoglobin level, neurocognitive markers, symptoms, and whether or not darbepoietin-alfa was administered to subjects with a hemoglobin level less than or equal to 11 g/dL. Results from this study may provide the necessary data to support a large-scale study examining the role of chemotherapy, cognitive function, and quality of life in breast cancer patients.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2004
- Accession Number
- ADA430387
Entities
People
- Jennifer R. Klemp
Organizations
- University of Kansas Medical Center